Hutchison China MediTech Limited (NASDAQ:HCM) was upgraded by equities researchers at BidaskClub from a “hold” rating to a “buy” rating in a report issued on Wednesday.

Several other brokerages also recently commented on HCM. Canaccord Genuity set a $30.00 target price on shares of Hutchison China MediTech Limited and gave the company a “buy” rating in a research note on Monday, July 31st. Zacks Investment Research downgraded shares of Hutchison China MediTech Limited from a “hold” rating to a “sell” rating in a research note on Monday, May 15th. One analyst has rated the stock with a sell rating and four have given a buy rating to the stock. The company currently has an average rating of “Buy” and a consensus price target of $28.00.

Shares of Hutchison China MediTech Limited (NASDAQ:HCM) opened at 25.43 on Wednesday. The company has a 50 day moving average of $24.45 and a 200-day moving average of $20.87. The firm has a market cap of $3.09 billion, a PE ratio of 239.91 and a beta of -2.00. Hutchison China MediTech Limited has a 12-month low of $10.61 and a 12-month high of $27.96.

ILLEGAL ACTIVITY WARNING: This news story was first reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this news story on another site, it was illegally stolen and reposted in violation of US and international trademark & copyright law. The correct version of this news story can be accessed at https://www.thecerbatgem.com/2017/09/08/hutchison-china-meditech-limited-hcm-stock-rating-upgraded-by-bidaskclub.html.

Several institutional investors have recently added to or reduced their stakes in the stock. Baillie Gifford & Co. raised its holdings in shares of Hutchison China MediTech Limited by 2.7% in the first quarter. Baillie Gifford & Co. now owns 157,892 shares of the company’s stock valued at $3,150,000 after buying an additional 4,189 shares during the last quarter. The Manufacturers Life Insurance Company raised its holdings in shares of Hutchison China MediTech Limited by 7.7% in the second quarter. The Manufacturers Life Insurance Company now owns 103,799 shares of the company’s stock valued at $2,420,000 after buying an additional 7,400 shares during the last quarter. Renaissance Technologies LLC bought a new position in shares of Hutchison China MediTech Limited in the first quarter valued at about $618,000. Wellington Management Group LLP raised its holdings in shares of Hutchison China MediTech Limited by 7.4% in the first quarter. Wellington Management Group LLP now owns 510,826 shares of the company’s stock valued at $10,190,000 after buying an additional 35,053 shares during the last quarter. Finally, Schroder Investment Management Group raised its holdings in shares of Hutchison China MediTech Limited by 6.8% in the first quarter. Schroder Investment Management Group now owns 976,364 shares of the company’s stock valued at $20,084,000 after buying an additional 62,045 shares during the last quarter. 4.06% of the stock is owned by institutional investors and hedge funds.

Hutchison China MediTech Limited Company Profile

Hutchison China MediTech Limited (Chi-Med) is a China-based, globally-focused healthcare group. The Company researches, develops, manufactures and sells pharmaceuticals and health-related consumer products. Its Innovation Platform focuses on discovering and developing therapeutics in oncology and autoimmune diseases for the global market.

Receive News & Stock Ratings for Hutchison China MediTech Limited Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hutchison China MediTech Limited and related stocks with our FREE daily email newsletter.